Shares of Owens & Minor, Inc. (NYSE:OMI – Get Rating) hit a new 52-week low during trading on Wednesday . The company traded as low as $26.27 and last traded at $26.33, with a volume of 4157 shares. The stock had previously closed at $26.95.
Wall Street Analysts Forecast Growth
OMI has been the subject of several recent research reports. Credit Suisse Group cut their target price on shares of Owens & Minor from $43.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, August 4th. Citigroup lowered their target price on shares of Owens & Minor from $58.00 to $52.00 in a report on Thursday, August 4th. Finally, Robert W. Baird decreased their price target on shares of Owens & Minor from $70.00 to $62.00 and set an “outperform” rating on the stock in a research note on Thursday, August 4th.
Owens & Minor Stock Down 1.5 %
The company has a market capitalization of $1.90 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 1.67 and a beta of 0.60. The business’s 50-day simple moving average is $31.87 and its 200-day simple moving average is $35.77. The company has a current ratio of 1.55, a quick ratio of 0.58 and a debt-to-equity ratio of 2.68.
Insider Transactions at Owens & Minor
In related news, COO Jeffrey T. Jochims sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $31.31, for a total value of $250,480.00. Following the completion of the transaction, the chief operating officer now directly owns 195,956 shares of the company’s stock, valued at $6,135,382.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Robert J. Henkel bought 1,000 shares of the stock in a transaction on Friday, July 15th. The shares were bought at an average price of $31.76 per share, with a total value of $31,760.00. Following the completion of the acquisition, the director now owns 27,000 shares of the company’s stock, valued at $857,520. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeffrey T. Jochims sold 8,000 shares of the stock in a transaction on Friday, July 1st. The shares were sold at an average price of $31.31, for a total value of $250,480.00. Following the sale, the chief operating officer now directly owns 195,956 shares in the company, valued at approximately $6,135,382.36. The disclosure for this sale can be found here. Corporate insiders own 4.09% of the company’s stock.
Hedge Funds Weigh In On Owens & Minor
Large investors have recently added to or reduced their stakes in the business. Profund Advisors LLC lifted its position in Owens & Minor by 24.6% during the first quarter. Profund Advisors LLC now owns 10,381 shares of the company’s stock worth $457,000 after buying an additional 2,050 shares during the period. Sciencast Management LP purchased a new position in shares of Owens & Minor in the 1st quarter worth about $343,000. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income raised its holdings in shares of Owens & Minor by 5.6% in the 1st quarter. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income now owns 291,670 shares of the company’s stock worth $12,839,000 after purchasing an additional 15,475 shares during the period. Great Lakes Advisors LLC purchased a new stake in shares of Owens & Minor during the 1st quarter valued at about $12,164,000. Finally, Brown Advisory Inc. raised its holdings in shares of Owens & Minor by 8.2% during the 1st quarter. Brown Advisory Inc. now owns 1,548,438 shares of the company’s stock valued at $68,141,000 after buying an additional 117,559 shares during the period. 95.69% of the stock is currently owned by hedge funds and other institutional investors.
About Owens & Minor
Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers.
- Get a free copy of the StockNews.com research report on Owens & Minor (OMI)
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Owens & Minor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Owens & Minor and related companies with MarketBeat.com's FREE daily email newsletter.